Editorial
Hormonal Replacement Therapy: Quo Vadis?
Abstract
The National Institutes of Health (NIH) sent shock waves through the medical community on July 9, 2002, when it announced the premature termination of the arm of the Women’s Health Initiative Study in which volunteers were randomly allocated to either a combination of conjugated equine estrogen and medroxyprogesterone acetate or a placebo. This course of action was due to the belief that the disadvantages derived from this hormonal replacement therapy (HRT) outweighed any potential advantage. Many professionals and a large part of the community were nonetheless astounded by this unexpected news.This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
